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Purpose: To evaluate the safety of intravitreal injection of Stivant, a biosimilar to
bevacizumab, in rabbits using electrophysiological and histological analysis.
Methods: Both eyes of 41 New Zealand albino rabbits were injected with 0.1 mL
(2.5 mg) of Stivant. The rabbits were scheduled to be sacrificed 1, 2, 7, 14, and
28 days after injection for histopathological evaluations. Clinical examinations and
electroretinography (ERG) were performed at baseline and just before sacrificing
the rabbits. Fourteen separate rabbits received a reference drug (Avastin) and were
considered as the control group. Furthermore, three other rabbits received the same
volume of saline (saline control group). Rabbits of both control groups were sacrificed
four weeks after injection. ERG was performed 1, 2, 7, 14, and 28 days after injections.
Results:No significant difference was observed in a- and b-wave amplitudes and latency
after intravitreal Stivant injection between baseline and different time points. Moreover,
there was no statistically significant difference in wave amplitudes and latency between
the Stivant and control groups. The histology of rabbit eyes of the Stivant and control
groups after intravitreal injections was not distinguishable.
Conclusion: The biosimilar Stivant, up to a dose of 2.5 mg, did not appear to be toxic
to the retina in albino rabbits. These results suggest that this drug could be a safe and
inexpensive alternative to intravitreal bevacizumab. The efficacy of these injections was
not investigated in this study and needs to be evaluated in future studies.
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Vascular endothelial growth factor (VEGF)
plays a substantial role in angiogenesis and
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vasculogenesis. Therefore, it is the main target for
the treatment of cancers and ophthalmic vascular
disorders.[1, 2] The inhibition of VEGF causes
regression of aberrant new vessels in experimental
models of proliferative vascular retinopathies and
neovascularization of the choroid.[3]
In 2004, bevacizumab, a humanized full-length
immunoglobulin G against VEGF, was approved
by the US Federal Drug Administration for the
management of colon cancer.[4] Bevacizumab is
now being used as an “off-label” intravitreal agent
for wet age-related macular degeneration (AMD),
diabetic retinopathy, and retinal vein occlusions
globally.[5] Intravitreal injections of ranibizumab
and aflibercept are both approved for wet-type
AMD and macular edema due to retinal vascular
disorders. However, despite similar efficacy
to bevacizumab, there are large differences
between the costs of these drugs. On an average,
bevacizumab is 20 times less expensive than
ranibizumab and aflibercept.[6]
A biosimilar is “essentially the same” as a
reference biologic in terms of structure, efficacy,
safety, and quality, although it has some natural
variability owing to its complex nature and
production methods.[7] Biosimilars, which are
economically more viable, have the potential
to reduce healthcare costs relative to reference
biologics, thereby increasing treatment access for
patients who need them.[8, 9] Stivant (CinnaGen
Co., Tehran, Iran) has been developed as a
biosimilar to a reference product, bevacizumab
(Avastin: Genentech, Inc., South San Francisco,
CA). Stivant is formulated with the same excipients
as the reference product and is provided in the
same pharmaceutical form and dosage strength.
Avastin® and Stivant have similar safety and
efficacy as intravenous injections for metastatic
colorectal cancer and have been approved for this
use.
To determine the safety of intravitreal injection
of this biosimilar drug, the albino rabbits were
injected intravitreally with Stivant and evaluated
for any functional and histological changes in the
retina.
METHODS
Forty-one albino New Zealand rabbits, weighing
between 1.5 and 2.5 kg, were used to evaluate
the safety of intravitreal Stivant injection. The
rabbits were treated in agreement with the
statement for the use of animals in ophthalmic and
vision research, proposed by The Association for
Research in Vision and Ophthalmology. The study
design was approved by the Institutional Review
Board of Tehran University of Medical Sciences.
The rabbits were kept in an air-conditioned
room with a 12-hour light–dark cycle and fed
with standard processed laboratory food. Seven
and eight of the rabbits were scheduled to
be sacrificed 24 and 48 hours after injection,
respectively, and the remaining were divided into
three separate groups to be sacrificed at one
(seven rabbits), two (ten rabbits), and four weeks
(nine rabbits) after injection. Clinical examinations
and electroretinography (ERG) were performed
at baseline and just before killing the rabbits
(Table 1). Fourteen separate rabbits received a
reference drug (Avastin: Genentech, Inc., South
San Francisco, CA) and were considered as the
control group. Furthermore, three other rabbits
received the same volume of normal saline and
were considered as the saline control group. Both
control groups were sacrificed four weeks after
injection; however the ERG for these groups was
performed 1, 2, 7, 14, and 28 days after injections
(Table 1).
Rabbits with documented anterior or posterior
segment abnormalities in the eye were
excluded. The animals were anesthetized
before all procedures using a mixture of
xylazine hydrochloride (5 mg/kg) and ketamine
hydrochloride (50 mg/kg). Before each
examination, the pupil of the eyes was dilated
by topical application of tropicamide 0.5% eye
drop.
Preparation and injection of the drugs
Under standard sterile conditions, standard
tuberculin syringes with 29-gauge needles were
filled with the drugs or saline. Intravitreal injections
of the drugs in each group were performed after
baseline examinations and baseline ERG. Rabbits
were anesthetized with an intramuscular injection
of the mixture of xylazine and ketamine. The eye
was prepped with installation of the 5% diluted
povidone iodine solution into the fornixes.
Both eyes of each rabbit in the Stivant and
Avastin groups were injected with 0.1 mL (2.5 mg)
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Table 1. Number of rabbits in each group
Number of rabbits Time for enucleation and scarification
Group 1 (Stivant) 7 1 day after injection
Group 2 (Stivant) 8 2 days after injection
Group 3 (Stivant) 7 1 week after injection
Group 4 (Stivant) 10 2 weeks after injection
Group 5 (Stivant) 9 4 weeks after injection
Control (Saline) 3 4 weeks after injection
Control (Avastin) 14 4 weeks after injection
Table 2. The amplitudes and latency times of ERG waves from the Stivant-treated rabbits
Groups a-wave Amplitude b-wave Amplitude a-wave Latency Time b-wave Latency Time
24 hours (14 eyes) *
Pre-treatment –38.5 ± 5.5 µV ** 97.1 ± 12 µV 13.9 ± 0.6 ms 32.6 ± 3.3 ms
Post-treatment –36.1 ± 3.4 µV 99.1 ± 22.1 µV 13.9 ± 0.7 ms 32.3 ± 3.1 ms
Difference in Decrease 6.2% Increase 2.1% Increase 0.1% Decrease 1%
48 hours (16 eyes) %
Pre-treatment –34.8 ± 3.6 µV 91.7 ± 9.5 µV 13.5 ± 0.5 ms 33.6 ± 2.7 ms
Post-treatment –32.6 ± 5.9 µV 98.8 ± 11.9 µV 14.1 ± 0.5 ms 35.1 ± 3.4 ms
Difference in Decrease 6.4% Increase 7.2% Increase 4.3% Increase 4.3%
1 week (14 eyes) %
Pre-treatment –47.2 ± 6 µV 128.5 ± 21.1 µV 13.9 ± 0.6 ms 35.3 ± 2.6 ms
Post-treatment –37.9 ± 9.2 µV 127.2 ± 38.3 µV 14.8 ± 0.7 ms 37.3 ± 1.9 ms
Difference in Decrease 19.8% Decrease 1.1% Increase 6.1% Increase 5.4%
2 weeks (20 eyes) %
Pre-treatment –48.2 ± 10.3 µV 140.3 ± 21.7 µV 14.1 ± 0.7 ms 36.6 ± 0.9 ms
Post-treatment –47.7 ± 9.5 µV 147.5 ± 21.5 µV 14.3 ± 0.6 ms 37.7 ± 1.1 ms
Difference in Decrease 1.1% Increase 4.9% Increase 1.4% Increase 3%
4 weeks (18 eyes) %
Pre-treatment –46.5 ± 7.1 µV 127.9 ±22.7 µV 14.7 ± 0.7 ms 36.1 ± 1.3 ms
Post-treatment –48.6 ± 14.1 µV 115.3 ± 30.1 µV 15.1 ± 0.5 ms 37 ± 2.1 ms
Difference in % Increase 4.4% Decrease 9.9% Increase 2.7% Increase 2.5%
*After injections; **Data are expressed as mean ± SD
Microvolts (µV); Milliseconds (ms)
of the drugs. Intravitreal injections into the mid-
vitreous cavity were performed 1.5 mm posterior
to the limbus. Anterior chamber paracentesis was
done before intravitreal injections with a 29-gauge
needle, withdrawing at least 0.05 mL of the
aqueous fluid to prevent intraocular pressure rise
after injections and also to prevent reflux from
the injection site. The same volume (0.1 mL) of
normal saline was injected into both eyes of each
of the three control rabbits in the same manner.
Ciprofloxacin and timolol eye drops were applied
to the eyes for the first three days after injections.
Clinical observations
The eyes were examined clinically at baseline
on the first and second days after injections
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Table 3. The amplitudes and latency times of ERG waves from the Avastin-treated rabbits (28 eyes)
Groups a-wave Amplitude b-wave Amplitude a-wave Latency Time b-wave Latency Time
24 hours (n = 28) *
Pre-treatment –37.8 ± 3 µV ** 120.1 ± 14.7 µV 14.5 ± 0.5 ms 34.4 ± 1.5 ms
Post-treatment –35.8 ± 2.8 µV 114.8 ± 13.8 µV 13.9 ± 0. 7 ms 35.1 ± 1.3 ms
Difference in Decrease 5.3% Decrease 4.5% Decrease 4.2% Increase 2%
48 hours (n = 28) %
Pre-treatment –37.8 ± 3 µV 120.1 ± 14.7 µV 14.5 ± 0.5 ms 34.4 ± 1.5 ms
Post-treatment –34.7 ± 5.9 µV 100.8 ± 13.6 µV 14.7 ± 0.3 ms 37.3 ± 1 ms
Difference in Decrease 8.3% Decrease 16.6% Increase 1.3% Increase 8.4%
1 week (n = 28) %
Pre-treatment –37.8 ± 3 µV 120.1 ± 14.7 µV 14.5 ± 0.5 ms 34.4 ± 1.5 ms
Post-treatment –32.9 ± 5.8 µV 106.5 ± 21.7 µV 14.3 ± 0.9 ms 32.5 ± 2.3 ms
Difference in Decrease 13 % Decrease 11.4% Decrease 1.4% Decrease 5.6%
2 weeks (n = 28) %
Pre-treatment –37.8 ± 3 µV 120.1 ± 14.7 µV 14.5 ± 0.5 ms 34.4 ± 1.5 ms
Post-treatment –44.5 ± 9.9 µV 134.4 ± 22.1 µV 13.6 ± 0.5 ms 35.1 ± 1.1 ms
Difference in Increase 17% Increase 11% Decrease 6.3% Increase 2%
4 weeks (n = 28) %
Pre-treatment –37.8 ± 3 µV 120.1 ± 14.7 µV 14.5 ± 0.5 ms 34.4 ± 1.5 ms
Post-treatment –42.6 ± 10.5 µV 110.4 ± 14.7 µV 14.2 ± 0.2 ms 33.2 ± 2.6 ms
Difference in % Increase 12.6% Decrease 8.1% Decrease 2.1% Decrease 3.5%
*After injections; **Data are exprssed as mean ± SD
Microvolts (µV); Milliseconds (ms)
and at the end of the first, second, and fourth
weeks of injections just before enucleation. The
following parameters were recorded: injection of
the conjunctiva, status of the cornea, appearance
of the crystalline lens, any pathologic findings in
the retina, and any cell or flare in the anterior and
posterior segments of the eye.
A hand-held slit lamp was used to evaluate
the status of the anterior segment. The anterior
chamber and vitreous cavity were carefully
examined with the highest magnification to detect
any cell or flare. At each follow-up, all eyes
underwent indirect ophthalmoscopy.
Electrophysiology
Electroretinography using the electrophysiological
test system (Metrovision, France) was performed
on both eyes of each rabbit at baseline and
the time points previously mentioned. All
rabbits underwent dark adaptation overnight
before ERG tests and were prepared for the
procedure under red light. The animals were
anesthetized, and corneal surface anesthesia was
achieved using tetracaine hydrochloride 0.5%.
Flashlight intensity of 10 cdsm−2 was used for
each recording; the average of the responses
from four separate light stimuli was documented.
ERG was recorded using a corneal contact lens
electrode (Metrovision, France). The ground
electrode was inserted into the ear, and the
negative electrode was attached near the orbital
rim.
The amplitude and implicit time measurements
of the a- and b-waves were used to evaluate ERG
responses. The a-wave amplitude was measured
from the baseline to the first trough; the b-wave
amplitudewasmeasured from the a-wave trough to
the peak of the b-wave. Latencies of the a- and b-
waves were measured from the time of presenting
the stimuli.
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Table 4. The amplitudes and latency times of ERG waves from the Saline-treated rabbits (6 eyes)
Groups a-wave Amplitude b-wave Amplitude a-wave Latency Time b-wave Latency Time
24 hours (n = 6) *
Pre-treatment –34.6 ± 2.1 µV ** 114.8 ± 17.7 µV 12.4 ± 1.1 ms 33.2 ± 2.1 ms
Post-treatment –32.9 ± 7.8 µV 106.4 ± 12.7 µV 13.2 ± 0.1 ms 34.2 ± 0.3 ms
Difference in Decrease 5% Decrease 6.6% Increase 6.4% Increase 3%
48 hours (n = 6) %
Pre-treatment –34.6 ± 2.1 µV 114.8 ± 17.7 µV 12.4 ± 1.1 ms 33.2 ± 2.1 ms
Post-treatment –33.5 ± 8.8 µV 101.4 ± 19.2 µV 14.7 ± 0.7 ms 35.6 ± 1.2 ms
Difference in Decrease 3.2% Decrease 11.7% Increase 18.5% Increase 7.2%
1 week (n = 6) %
Pre-treatment –34.6 ± 2.1 µV 114.8 ± 17.7 µV 12.4 ± 1.1 ms 33.2 ± 2.1 ms
Post-treatment –40 ± 8.1 µV 129.9 ± 27.2 µV 14.1 ± 0.6 ms 35.1 ± 1.6 ms
Difference in Increase 15.6 % Increase 13.1% Increase 13.7% Increase 5.7%
2 weeks (n = 6) %
Pre-treatment –34.6 ± 2.1 µV 114.8 ± 17.7 µV 12.4 ± 1.1 ms 33.2 ± 2.1 ms
Post-treatment –38.6 ± 8.4 µV 135.3 ± 28.3 µV 14.3 ± 0.7 ms 35.9 ± 1.5 ms
Difference in Increase 11.5% Increase 17.8% Increase 15.3% Increase 8.1%
4 weeks (n = 6) %
Pre-treatment –34.6 ± 2.1 µV 114.8 ± 17.7 µV 12.4 ± 1.1 ms 33.2 ± 2.1 ms
Post-treatment –41.5 ± 13.3 µV 110.3 ± 20.5 µV 14.1 ± 0.6 ms 35.2 ± 2.1 ms
Difference in % Increase 19.8% Decrease 4% Increase 13.7% Increase 6%
*After injections; **Data are expressed as mean ± SD
Microvolts (µV); Milliseconds (ms)
Histopathologic examinations
After the last ophthalmoscopy and
electrophysiology in each group, the animals
were sacrificed by intravenous injection of 100
mg/kg of sodium pentobarbital while under deep
anesthesia. With careful attention to prevent
any damage to globe integrity, the eyes were
enucleated. Then, each enucleated eye was
promptly placed in a separate bottle containing
the neutral formalin solution. After seven days,
samples were fixed in paraffin. Microtome sections
of 5-m thickness were prepared and stained with
hematoxylin-eosin. Slides were examined under a
light microscope.
Statistical Analysis
Statistical analysis was performed using the
SPSS software version 24.0. (IBM SPSS Statistics
for Windows, Armonk, NY: IBM Corp). One-way
analysis of variance was used to determine
whether there were any statistically significant
differences between the groups, based on the ERG
parameters. The generalized estimating equation
(GEE) regression model was used to analyze the
effect of the injections on the ERG a- and b-wave
amplitudes and implicit time between the Stivant
and control groups, separately. A P-value < 0.05
was considered statistically significant.
RESULTS
Of 41 rabbits in the Stivant group, 3 were excluded
due to death; 1 died just after injection, and the
other 2 died five days and three weeks after
injection, respectively. Stivant was tolerated well in
the remaining rabbits. Two rabbits also died two
weeks after injection in the Avastin control group.
No obvious changes in food or water intake were
observed.
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Table 5. Comparison of the amplitudes and latency times of rod responses from the Stivant-treated rabbits, saline-treated
rabbits, and Avastin-treated rabbits
Groups a-wave Amplitude b-wave Amplitude a-wave Latency Time b-wave Latency Time
24 hours
Saline (n* = 6) –32.9 ± 7.8 µV 106.4 ± 12.7 µV 13.2 ± 0.1 ms 34.2 ± 0.3 ms
Avastin (n = 28) –35.8 ± 2.8 µV 114.8 ± 13.8 µV 13.9 ± 0. 7 ms 35.1 ± 1.3 ms
Stivant (n = 14) –36.1 ± 3.4 µV 99.1 ± 22.1 µV 13.9 ± 0.7 ms 32.3 ± 3.1 ms
P-value** Stivant/saline 0.43 0.54 0.86 0.71
Stivant/Avastin 0.73 0.21 0.79 0.69
48 hours
Saline (n = 6) –33.5 ± 8.8 µV 101.4 ± 19.2 µV 14.7 ± 0.7 ms 35.6 ± 1.2 ms
Avastin (n = 28) –34.7 ± 5.9 µV 100.8 ± 13.6 µV 14.7 ± 0.3 ms 37.3 ± 1 ms
Stivant (n = 16) –32.6 ± 5.9 µV 98.8 ± 11.9 µV 14.1 ± 0.5 ms 35.1 ± 3.4 ms
P-value** Stivant/saline 0.38 0.44 0.88 0.90
Stivant/Avastin 0.33 0.29 0.81 0.76
1 week
Saline (n = 6) –40 ± 8.1 µV 129.9 ± 27.2 µV 14.1 ± 0.6 ms 35.1 ± 1.6 ms
Avastin (n = 28) –32.9 ± 5.8 µV 106.5 ± 21.7 µV 14.3 ± 0.9 ms 32.5 ± 2.3 ms
Stivant (n = 14) –37.9 ± 9.2 µV 127.2 ± 38.3 µV 14.8 ± 0.7 ms 37.3 ± 1.9 ms
P-value** Stivant/saline 0.19 0.33 0.87 0.53
Stivant/Avastin 0.16 0.11 0.75 0.28
2 weeks
Saline (n = 6) –38.6 ± 8.4 µV 135.3 ± 28.3 µV 14.3 ± 0.7 ms 35.9 ± 1.5 ms
Avastin (n = 28) –44.5 ± 9.9 µV 134.4 ± 22.1 µV 13.6 ± 0.5 ms 35.1 ± 1.1 ms
Stivant (n = 20) –47.7 ± 9.5 µV 147.5 ± 21.5 µV 14.3 ± 0.6 ms 37.7 ± 1.1 ms
P-value** Stivant/saline 0.14 0.18 0.94 0.72
Stivant/Avastin 0.81 0.09 0.61 0.66
4 weeks
Saline (n = 6) –41.5 ± 13.3 µV 110.3 ± 20.5 µV 14.1 ± 0.6 ms 35.2 ± 2.1 ms
Avastin (n = 28) –42.6 ± 10.5 µV 110.4 ± 14.7 µV 14.2 ± 0.2 ms 33.2 ± 2.6 ms
Stivant (n = 18) –48.6 ± 14.1 µV 115.3 ± 30.1 µV 15.1 ± 0.5 ms 37 ± 2.1 ms
P-value** Stivant/saline 0.14 0.68 0.88 0.67
Stivant/Avastin 0.30 0.58 0.24 0.54
Data are expressed as mean ± SD
*Number of the injected eyes in each group; **Based on generalized estimating equation (GEE) regression model
Microvolts (µV); Milliseconds (ms)
Clinical Evaluation
At each anterior segment examination, there was
no new significant abnormality in conjunctiva or
different layers of the cornea. Anterior chamber
or vitreous cells were not detected in any eye
at different time points on biomicroscopic
examination. There was no iris abnormality in
any eye of each group. The crystalline lenses
were clear. The vitreous, retina, choroid, and
optic nerve seemed normal, based on indirect
ophthalmoscopy.
Electrophysiology
There was no significant difference between
ERG wave amplitudes and implicit times between
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Stivant, Avastin, and saline groups at baseline. ERG
changes were considered significant at each time
point if the difference in amplitudes (a- and b-
waves) was more than 20% of the baseline values.
The ERG results of the Stivant, Avastin, and
saline groups are presented in Tables 2, 3, and
4, respectively. Dark-adapted bright flash ERG was
performed for all rabbits before the intravitreal
injection as a baseline standard and then at
each time point. Despite a 19.8% decrease in the
amplitude of the a-wave on day 7 after Stivant
injection, no significant change was found in the
a-wave amplitude and implicit time after injections
in each group. We also observed a 13% reduction
in the a-wave amplitude, one week after Avastin
injection. These reductions were reversed just one
week later in both groups.
This study did not show a significant change in
the amplitude and latency of b-waves in Stivant and
Avastin groups, although, when compared to the
baseline, the b-wave amplitude decreased 9.9%
and 8.1% in eyes that were evaluated four weeks
after Stivant and Avastin injections, respectively.
There were no statistically significant differences
between the Stivant, Avastin, and saline groups,
based on ERG parameters. Also, based on the
GEE regression model, there was no significant
difference between the Stivant-injected eyes and
the Avastin and saline control groups at each time
point, separately. (Table 5)
Histological Findings
Based on histopathological findings, there were
no distinguishable changes in both the Stivant
and control groups after intravitreal injections.
There were no signs of ocular toxicity, based on
histological evaluations in the groups.
In the light microscopic slides, there was
no evidence of corneal deposits, thinning,
or endothelial cell damage in the cornea.
Uveal tissue did not show any inflammation
or neovascularization. There was no sign
of inflammation in the anterior and posterior
segments of the eyes.
There was no evidence of intraocular
hemorrhage in specimens, except the right eye of
a rabbit that was sacrificed two weeks after Stivant
injection. The right eye showed retinal and vitreous
hemorrhage, although there was no significant
change in ERG parameters from baseline in this
eye.
All specimens had normal retinal thickness,
ganglion cells, photoreceptor morphology,
pigmented epithelial cells, and nuclear layers.
No evidence of optic nerve edema, neuritis, or
atrophy was identified.
The only positive histopathological finding was
congestion of the choroid without hemorrhage in
half of the eyes that were injected with Stivant,
which were enucleated 24 hours after injection.
This finding was not observed in Stivant-injected
groups at other time points (Figure 1).
DISCUSSION
Our results showed that a single intravitreal
injection of the biosimilar to bevacizumab (Stivant)
at doses up to 2.5 mg in albino rabbit eyes did
not result in apparent vitreoretinal toxicity at
1, 2, 7, 14, and 28 days after injection, based
on electrophysiological and histopathological
findings. The ERG responses of the experimental
and two control group eyes were similar in a- or
b-wave amplitudes and implicit times at different
time points after injections.
Anti-VEGF agents play a key role in the
management of different retinal conditions,
such as wet AMD, diabetic macular edema, and
retinal vein occlusion.[10–12] As most of these
patients need multiple anti-VEGF injections, these
drugs incur high individual, medical, and societal
costs.[13] By decreasing the cost of therapy, the
economic burden on the individual patients, their
families, and society will be reduced. In developing
countries, the high cost of treatment is an important
limiting factor for patient compliance to anti-VEGF
agents.[13, 14]
Biosimilar drugs, in comparison with reference
products, have the same structure, efficacy,
safety, and quality, although there may be
slight differences due to the complexities of
the production process.[7, 8] As both the reference
and biosimilar drugs have a degree of natural
variability, studies are necessary to ensure
that these differences do not affect the safety
of intravitreal injection of these drugs. These
biosimilar drugs can increase the community
access to biological drugs, such as anti-VEGF
agents, and can also reduce the burden on the
healthcare budget.[15]
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Figure 1. Representative histopathological sections from injected eyes four weeks after injection: there is preservation of the
retinal cytoarchitecture without loss of the inner and outer nuclear layers or the inner and outer plexiform layers in both Avastin-
injected (a) and Stivant-injected eyes (b) (Staining: hematoxylin and eosin [H&E], magnification: ×40).
The biosimilar ranibizumab (Razumab®; Intas
Pharmaceuticals) is the first ophthalmic biosimilar
that has been developed in India.[7] It has
undergone animal safety studies and larger
humanized head-to-head studies to ensure
close resemblance in pharmacokinetic and
pharmacodynamics characteristics, safety, and
efficacy to the reference drug. Intravitreal injection
of Zybev (a biosimilar of bevacizumab) has also
shown to be safe, based on different studies.[16]
The bevacizumab biosimilar (Stivant; CinnaGen
Co) is the first biosimilar to an anti-VEGF agent
that has been developed in Iran. Large studies
in patients with systemic cancers have been
conducted to ensure close resemblance in safety
and efficacy with the reference product (Avastin®).
To assess the safety of intravitreal injection of
this biosimilar drug, we performed intravitreal
injections of Stivant at the double dosage in albino
New Zealand rabbits and investigated the retinal
function and histological findings. The intravitreal
injection of bevacizumab may be potentially toxic
to the eye through the following threemechanisms:
first, the vehicle could be toxic itself; second,
toxicity could be due to induction of an immune
response by injecting an immunoglobulin; and
third, toxicity could be due to interference with
endogenous VEGF signaling.[27]
Manzano et al[17] evaluated the safety of
the intravitreal injection of the reference drug
(Avastin®). They defined at least a 30% reduction
in ERG wave amplitudes to be significant, whereas
we considered a lower threshold (20%) for ERG
amplitude and latency changes to be significant.
The ERG wave amplitude and latency changes
were less than 10% at different time points in our
study, except for a 19.8% reduction in a wave
amplitude at week 1 after Stivant injection. This
reduction was not observed two and four weeks
after injections. One week after Avastin injection,
we also observed a 13% reduction in the a-wave
amplitude, which was reversed in the following
weeks. These reductions may be due to a transient
effect of the drugs on photoreceptors in the early
post-injection period. We observed a similar but
earlier reduction in the wave amplitude after saline
injection; 48 hours post injection.
In this study, we report that intravitreal injection
of a high dose of the biosimilar bevacizumab
(Stivant) in rabbit eyes is well tolerated, at least
in the short-term. The vitreous volume of a rabbit
eye is approximately 1.5 mL and that of a human
eye is approximately 5 mL. As the dose of 1.25
mg of bevacizumab is frequently used in humans,
the doses of 1.25 and 2.5 mg of bevacizumab in
rabbits result in approximately 3.3 and 6.6 times
concentration of the medication in human eyes,
respectively. Similar to some previous studies that
evaluated the safety profile of a new anti-VEGF
on the retinal tissue, we used 2.5 mg of this
biosimilar drug to evaluate the safety of a higher
concentration.[9] However, the maximum safe dose
of bevacizumab was not determined in this study.
This study has some limitations. The endpoint
ERG of the study group did not have a significant
change in parameters from baseline. However,
this study evaluated the short-term changes
after a single intravitreal injection and did not
rule out the possibility that long-term follow-
up, especially with more injections, might
demonstrate inappropriate side effects. As
ERG is primarily a functional test of the status
348 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 3, JULY-SEPTEMBER 2020
Stivant, a Bevacizumab Biosimilar; Lashay et al
of the photoreceptors and bipolar cells, normal
ERG results do not exclude possible damage
at the level of the retinal ganglion cells or their
axons, although this was not seen in histological
evaluations.[18, 19] Conversely, safety based on
histological findings by light microscopy does not
rule out possible changes at the submicroscopic
level.[20] Therefore, it is better to design a study
to perform immunocytochemical analysis on
the histopathologic sections to evaluate the
possible damage to retinal microstructures.
Another limitation of the study was the disparity
between the study group and the control groups in
terms of the number of anesthesia sessions before
enucleation and lack of tissue for histopathological
evaluation in the control groups at time points
earlier than four weeks after injections.
In summary, a single intravitreal injection of the
biosimilar to bevacizumab (Stivant) up to a dose of
2.5 mg (high concentration) in the eyes of albino
rabbits did not appear to be toxic for the retina.
These results suggest that this drug could be a
safe and cost-effective alternative to the reference
drug. However, further investigations are needed
to evaluate the long-term safety and efficacy of this
biosimilar drug.
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